ABIOMED (NASDAQ: ABMD) and PerkinElmer (NYSE:PKI) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Risk and Volatility

ABIOMED has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, PerkinElmer has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Earnings and Valuation

This table compares ABIOMED and PerkinElmer’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ABIOMED $474.78 million 13.77 $110.92 million $1.69 88.12
PerkinElmer $2.14 billion 3.36 $416.05 million $3.31 19.69

PerkinElmer has higher revenue and earnings than ABIOMED. PerkinElmer is trading at a lower price-to-earnings ratio than ABIOMED, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ABIOMED and PerkinElmer’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ABIOMED 16.13% 13.03% 10.98%
PerkinElmer 16.80% 13.44% 6.85%

Dividends

PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. ABIOMED does not pay a dividend. PerkinElmer pays out 8.5% of its earnings in the form of a dividend.

Insider & Institutional Ownership

91.1% of ABIOMED shares are owned by institutional investors. Comparatively, 91.5% of PerkinElmer shares are owned by institutional investors. 7.0% of ABIOMED shares are owned by insiders. Comparatively, 2.2% of PerkinElmer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for ABIOMED and PerkinElmer, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABIOMED 0 1 6 0 2.86
PerkinElmer 2 7 4 0 2.15

ABIOMED currently has a consensus target price of $157.50, indicating a potential upside of 5.75%. PerkinElmer has a consensus target price of $66.91, indicating a potential upside of 2.65%. Given ABIOMED’s stronger consensus rating and higher probable upside, analysts clearly believe ABIOMED is more favorable than PerkinElmer.

About ABIOMED

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

About PerkinElmer

PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.

Receive News & Stock Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related stocks with our FREE daily email newsletter.